By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ascletis, Inc. 

1785 Jianghai Road,building No.1
Suite 804
Binjiang District  Hangzhou    China
Phone: +86-571-8538-9729 Fax: n/a



Company News
Medivir (MVRBF) Licenses Exclusive Rights To MIV-802 For Greater China To Ascletis 8/18/2017 6:33:48 AM
Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen 6/21/2016 6:53:30 AM
Goldman, Sachs & Co. Invests US$20 Million In Ascletis, Inc. 12/2/2015 6:26:56 AM
Ascletis, Inc. Scores $35 Million Financing 9/2/2015 5:52:55 AM
Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan 8/31/2015 6:13:06 AM
Ascletis, Inc. As The First Chinese Company To File Clinical Applications For Interferon-Free HCV Treatment 6/24/2015 8:04:50 AM
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug 3/18/2015 9:30:30 AM
Ascletis, Inc. Gains China Market Rights From Janssen Research & Development to a Clinical Stage HIV Protease Inhibitor 4/30/2013 10:55:32 AM
Week in Review: Ascletis, Inc. Collaborates With Roche (RHHBY) on HCV Treatment 4/22/2013 9:24:09 AM
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China 4/15/2013 8:46:10 AM